TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
In a personal essay published Oct. 6, 2026, patient advocate Ron Carr recounts how learning he carries two copies of APOE4 and later finding coronary artery plaque changed his approach to health risks. His account is a first-person perspective, not evidence that the notifications predict Alzheimer’s disease or that a particular prevention plan works for everyone.
Patient advocate Ron Carr says three health notifications changed how he thinks about Alzheimer’s risk: a genetic test showing two copies of APOE4, a coronary artery scan revealing calcified plaque, and a third notification described in the essay’s headline. In a personal account published by Being Patient on Oct. 6, Carr explains how the first two findings shifted his focus from fearing inherited risk to discussing prevention with clinicians.
Carr writes that he learned about his APOE4 status two years before publication. He initially treated the result as if it had rewritten his future, interpreting ordinary lapses in memory as possible warning signs. He says he responded by reading extensively about Alzheimer’s research and repeatedly changing his diet, exercise routine and supplement use. The account describes his experience and does not establish that these changes prevent dementia.
He says a clinician at the University of Southern California later discussed APOE4’s role in lipid transport and arranged a coronary artery calcium scan. Carr reports that the scan showed significant calcified plaque, concentrated mainly in the left anterior descending artery. He writes that follow-up care included efforts to lower his LDL cholesterol and ApoB, and that subsequent testing showed no evidence of structural heart damage.
The supplied essay excerpt identifies the genetic test and heart scan as the first two notifications, but ends before describing the third. Its details are therefore not confirmed in the available source material. Carr is identified as a retired local government executive and patient advocate who writes about Alzheimer’s prevention, genetic testing and cardiovascular health.
How Risk Findings Changed Carr’s Care
Carr’s account illustrates how a genetic risk result can lead someone to seek more information and discuss other health concerns with a clinician. His essay distinguishes a risk factor from a diagnosis: he says learning he carried two APOE4 copies initially prompted fear, while learning that genetic risk was not itself a diagnosis helped him feel less helpless.
The heart scan, as Carr describes it, changed the discussion from inherited susceptibility to a finding of coronary plaque that his clinical team addressed. His experience may prompt readers to ask how genetic information should be interpreted and what follow-up is appropriate. It does not show that every person with APOE4 needs the same tests or treatment, or that the scan finding predicts Alzheimer’s disease.
Carr also describes relying on his wife, Barb, while he searched for answers. That personal detail underscores that a health notification can affect daily life and family relationships as well as medical decisions. The essay offers an individual account, not a clinical recommendation.
genetic testing kit for Alzheimer’s risk
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From APOE4 Result to Heart Scan
APOE4 is a genetic variant associated with increased risk of late-onset Alzheimer’s disease, but carrying it does not by itself diagnose Alzheimer’s. Carr says he learned he had two copies and initially viewed the result as a forecast. Over time, he came to describe genetic testing as information that could guide conversations and choices rather than determine his future.
In the essay, Carr also cites a Lancet Commission estimate that up to 45% of dementia cases may be attributable to potentially modifiable risk factors. That figure is presented as a population-level estimate in his account; it does not mean an individual can prevent dementia or reduce personal risk by a particular amount. Carr’s reported heart scan followed discussions with a USC clinician about APOE4 and lipid transport, against the background of his father’s heart attack at age 65.
“APOE4 is not a diagnosis. It is a risk factor.”
— Ron Carr, in his Being Patient essay
As an affiliate, we earn on qualifying purchases.
The Third Notification Is Missing
The supplied excerpt does not include the essay’s third notification, so its subject and significance cannot be reported reliably here. It also does not give the scan’s calcium score, the precise amount of plaque, or the medication names and doses used in Carr’s care. Those details should not be inferred from his description.
The account does not provide independent medical records or establish that Carr’s interventions changed his Alzheimer’s risk. It is a personal essay, and the impact of APOE4 and cardiovascular findings varies by person. Readers’ own risk assessments and treatment decisions require discussion with qualified health professionals.
LDL cholesterol lowering supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Further Details Needed on Notification Three
The next step for understanding the headline’s full account is to consult the complete Being Patient essay, which may describe the third notification and any later developments. In the material available here, no additional test result or future clinical milestone is specified.
Carr’s account points to conversations with clinicians as part of his response to the findings. Anyone considering genetic testing or cardiovascular screening should discuss the potential benefits, limits and follow-up implications with a qualified health professional rather than treating a single personal story as a testing or treatment plan.
cardiovascular health monitoring devices
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did Carr say his APOE4 test showed?
Carr writes that he learned he carries two copies of APOE4. He describes the result as a risk factor, not a diagnosis of Alzheimer’s disease.
What did the coronary artery scan find?
Carr says the scan showed significant calcified plaque, concentrated mainly in his left anterior descending artery. The excerpt does not report a calcium score or detailed measurements.
What was the third health notification?
The provided excerpt ends before describing the third notification. Its details cannot be confirmed from the source material supplied.
Does carrying APOE4 mean someone will develop Alzheimer’s?
No. Carr’s essay describes APOE4 as a risk factor, not a diagnosis or certainty. Individual health decisions should be discussed with a qualified clinician.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
